相似文献
1
Nasal Glucagon.
Hosp Pharm. 2022 Dec;57(6):697-703. doi: 10.1177/0018578719888914. Epub 2019 Nov 15.
2
Comparison of Intranasal and Injectable Glucagon Administration Among Pediatric Population Responders.
Diabetes Technol Ther. 2023 Nov;25(11):808-816. doi: 10.1089/dia.2023.0290.
3
Emerging Adult and Caregiver Psychosocial Experiences with Severe Hypoglycemic Events and the Perceived Impact of Nasal Glucagon: A Cross-Sectional Study.
Diabetes Ther. 2023 Aug;14(8):1285-1298. doi: 10.1007/s13300-023-01425-1. Epub 2023 Jun 2.
4
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19.
5
Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
Diabetes Technol Ther. 2017 Jul;19(7):423-432. doi: 10.1089/dia.2016.0460. Epub 2017 May 30.
6
Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances.
Clin Ther. 2019 Oct;41(10):2073-2089.e6. doi: 10.1016/j.clinthera.2019.08.006. Epub 2019 Sep 13.
7
Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
J Med Econ. 2022 Jan-Dec;25(1):238-248. doi: 10.1080/13696998.2022.2035131.
8
Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients.
Diabetes Res Clin Pract. 1992 Jul;17(1):43-50. doi: 10.1016/0168-8227(92)90042-p.
9
Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study.
Diabetes Ther. 2020 Jul;11(7):1591-1603. doi: 10.1007/s13300-020-00845-7. Epub 2020 Jun 8.
10
Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device.
Cutan Ocul Toxicol. 2016 Sep;35(3):242-7. doi: 10.3109/15569527.2015.1089884. Epub 2015 Oct 1.
本文引用的文献
1
A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
Pediatr Diabetes. 2018 Aug;19(5):1007-1013. doi: 10.1111/pedi.12668. Epub 2018 Mar 22.
2
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
Diabetes Obes Metab. 2018 May;20(5):1316-1320. doi: 10.1111/dom.13278. Epub 2018 Mar 22.
3
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19.
4
Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
Diabetes Technol Ther. 2017 Jul;19(7):423-432. doi: 10.1089/dia.2016.0460. Epub 2017 May 30.
5
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.
Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.
6
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.
7
Characterization of a novel functional protein in the pancreatic islet: islet homeostasis protein regulation of glucagon synthesis in α cells.
Pancreas. 2012 Jan;41(1):22-30. doi: 10.1097/MPA.0b013e3182222ee5.
Zotero 插件